Actinium Pharmaceuticals, Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. The filing was signed March 31, 2023. It is an annual report, not a standalone fourth-quarter report.
Business context and reporting period
Actinium is a clinical-stage biopharmaceutical company developing targeted radiotherapies. Its lead programs are Iomab-B, a targeted conditioning and bridging treatment intended to enable bone marrow transplant (BMT) in relapsed or refractory acute myeloid leukemia (r/r AML), and Actimab-A, an investigational AML therapy. The company had no approved products and no commercial product-sales revenue in 2022.
Financial performance and position
| Metric | 2022 | 2021 |
|---|---|---|
| Commercial revenue | $0 | $0 |
| Other revenue | $1.03 million | $1.14 million |
| Research and development expense, net | $23.14 million | $18.03 million |
| General and administrative expense | $12.00 million | $8.08 million |
| Operating expenses | $35.13 million | $26.11 million |
| Net loss | $33.02 million | $24.77 million |
| Net loss per share, basic and diluted | $1.37 | $1.20 |
| Cash and cash equivalents at year-end | $108.91 million | $77.83 million |
Other revenue included research collaboration and grant revenue; the $35 million Immedica upfront payment was recorded as deferred license revenue, not recognized as 2022 revenue. The agreement also provides for potential regulatory and commercial milestones of up to $417 million and royalties in the mid-20% range on eligible net sales.
Reported operating cash flow was positive $8.64 million, versus cash used of $20.87 million in 2021, primarily because of the $35 million Immedica payment. Financing provided $23.11 million in 2022, mainly from common-stock sales; investing used $0.37 million. Cash, cash equivalents and restricted cash totaled $109.61 million at year-end, including $0.70 million restricted. The filing reports no off-balance-sheet arrangements and no material conventional debt; lease liabilities are disclosed separately.
At December 31, 2022, total current assets were $110.94 million and current liabilities were $10.63 million. Total liabilities were $47.71 million, including $35 million of deferred license revenue and lease obligations. Accumulated deficit was $288.77 million. Gross margin is not meaningful because the company had no commercial product sales.
Material changes versus 2021
- Net loss increased by $8.24 million, reflecting higher R&D and general and administrative costs, partly offset by higher interest income.
- R&D expense rose $5.10 million, mainly from increased Iomab-B chemistry, manufacturing and controls activity and higher compensation. General and administrative expense rose $3.92 million, including increased compensation, equity compensation, professional and consulting fees, and legal costs.
- Cash and cash equivalents increased by $31.08 million. The improvement in operating cash flow reflected the Immedica upfront payment; equity sales also contributed materially to funding.
- Common shares outstanding increased from 22.14 million at year-end 2021 to 25.67 million at year-end 2022. The company sold 3.51 million shares under its sales agreement for $23.16 million net proceeds.
Outlook, commentary, risks and unusual items
- Iomab-B: The company reported that the Phase 3 SIERRA trial met its primary endpoint of durable complete remission at 180 days, with p<0.0001. The filing describes 75% initial remission after BMT in the Iomab-B arm versus 6.3% in the control arm, and 22% versus none achieving durable remission. The intent-to-treat overall-survival secondary endpoint was not met; the filing says early crossover from control to Iomab-B confounded that analysis. Exploratory comparisons favored Iomab-B, but are not the same as a successful prespecified ITT OS endpoint.
- Regulatory and commercial plans: Management planned to pursue an early access program and submit an Iomab-B BLA in the second half of 2023, with a potential U.S. launch in 2024 if approved. These are forward-looking plans, not achieved milestones. Immedica holds EUMENA rights and is expected to pursue a European marketing application; the filing anticipated a 2024 filing.
- Actimab-A: Phase 1 combination results reported for Actimab-A plus CLAG-M included a 65% overall response rate, 52% complete remission rate, and 53% and 32% survival at one and two years, respectively. A February 2023 NCI collaboration was expected to support further development. These are clinical findings, not evidence of regulatory approval.
- Funding: Management stated that resources were expected to fund planned operations for more than 12 months after the filing date; elsewhere it described year-end cash of approximately $100 million as projected to fund operations through 2025. The company expects continuing losses and may need additional capital. Future equity financing could dilute shareholders.
- Key risks: Regulatory approval and commercialization remain uncertain; the business is highly dependent on Iomab-B and Actimab-A. Other material risks include trial execution and interpretation of evolving data, reimbursement and market adoption, reliance on third-party manufacturers and isotope suppliers, competition, patent uncertainty, and the need to build commercial capabilities.
- Other items: The filing disclosed a former employee trade-secret dispute and related injunction and arbitration proceedings. It reported no other legal proceedings expected to have a material adverse effect. The auditor issued an unqualified opinion on the financial statements and reported no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal control.
Most important facts for investors to verify
- Whether Actinium submitted the Iomab-B BLA on the stated timeline, and the FDA’s filing, review and approval decisions.
- Final and regulator-reviewed SIERRA data, especially endpoint definitions, crossover effects, safety findings, and the distinction between the unmet ITT OS endpoint and favorable exploratory analyses.
- Actual cash burn and runway against management’s projections, including the timing of future milestones, clinical costs and any additional financing or dilution.
- Progress and terms of Immedica’s European regulatory filing, and whether milestone or royalty revenue becomes achievable; the $35 million upfront remains deferred pending the specified regulatory event.
- Actimab-A development progress under the NCI collaboration, and whether early-stage combination findings are confirmed in later trials.
- Manufacturing readiness, isotope supply continuity, reimbursement prospects and the costs of establishing commercial operations.